Policy strategists to debate 2025 impact of the new administration and market changes to healthcare
Avalere, part of Avalere Health, convenes eleven strategists
WASHINGTON, Jan. 15, 2025 /PRNewswire/ -- Eleven leading policy strategists are scheduled to debate how market changes and the Trump administration will shape 2025, impacting drug pricing, health plan design and patient access to needed therapies. The annual live webinar, "2025 Healthcare Industry Outlook: Opportunity Through Uncertainty" is scheduled for Thursday, January 23 at 11:00 a.m. ET.
"As cost pressures and reimbursement changes continue to evolve, so too will the behaviors and incentives of manufacturers, payers, providers and patients," said Sarah Alwardt, Ph.D., president of Avalere, part of Avalere Health. "Avalere has convened 11 experts who will pinpoint which business priorities will be impacted in 2025 and how companies can move forward to thrive in this new environment." Based on multiple analyses, Dr. Alwardt has identified the primary trends to watch in 2025:
Adapting to cost pressures and reimbursement changes
- States that may cap prescription drug costs and the implications for reimbursement, cost sharing and physician behavior
- Strategies providers will execute to manage system-wide cost pressures
- The impact of price negotiation on physician-administered drugs
- The out-of-pocket spending increases that could occur when Medicare Part D plans shift their tiers to coinsurance-based cost sharing
Navigating the uncertainty of scientific progress and policy change
- The importance of demonstrating AI benefits to reduce apprehension
- The impact of maximum fair prices across the supply chain
- How federal vaccine policy may change with new key cabinet nominees
- Coverage strategies for GLP-1s
Building integrated business strategies in times of complexity
- Regulatory and coverage strategies for diagnostics, devices and technology
- Adapting health plan strategies and operations to increasing stakeholder demands
- Expanding prescription drug value with product reformulation plans
- Integrating health economics outcomes research with market access
The 11 Avalere strategists presenting on January 23 are listed below. To see each bio, click on the name. To register and attend the webinar, visit Avalere.com/Outlook or click here.
- Maddi Davidson, principal
- Lauren Makhoul (Cricchi), principal
- Milena Sullivan, practice director
- Nicole Betor, consultant II
- Ashley Flint, principal
- Mark Gooding, managing director
- Michael Lutz, managing director
- Robin Duddy-Tenbrunsel, principal
- Nancy El Hoyek, associate principal
- Brigit Kyei-Baffour, principal
- Eric Levine, associate principal
Avalere, part of Avalere Health, is a strategic advisory company whose core purpose is to create innovative solutions to complex healthcare problems. Based in Washington, D.C., the firm delivers objective analysis, actionable insights and data-driven solutions for leaders in the healthcare system. Avalere's experts are drawn from Fortune 500 healthcare companies, the federal government (e.g., CMS, OMB, CBO and Congress), top consultancies, and nonprofits. The firm offers deep substance on the full range of healthcare business issues affecting life sciences manufacturers; trade associations and patient advocacy groups; health plans and PBMs; and the financial services industry. Avalere's focus on strategy is supported by a rigorous, in-house analytic research group that uses public and private data to generate quantitative insights. Through events, publications and interactive programs, Avalere insights are accessible to a broad range of customers. For more information, visit avalere.com, or follow us on LinkedIn.
SOURCE Avalere Health
Share this article